Yun N Mo from New York, NY, age 53

Resumes

Senior Director, Pharmaceutical Development

view source

Location:

San Francisco, CA

Industry:

Pharmaceuticals

Work:

Nuvation Bio
Senior Director, Pharmaceutical Development
Biotie Therapies Corp. 2016 - 2017
Associate Director, Drug Product Development
Axovant Sciences 2016 - 2017
Director Pharmaceutical Development
Theravance Biopharma Us, Inc. 2014 - 2016
Group Leader In Pharmaceutical Development
Forest Labs 2007 - 2014
Cmc Team Leader and Formulation Scientist

Education:

National University of Singapore 2000 - 2004
Doctorates, Doctor of Philosophy, Philosophy China Pharmaceutical University 1996 - 1999
Master of Science, Masters China Pharmaceutical University 1992 - 1996
Bachelors

Skills:

Formulation
Pharmaceutical Process Development
Pharmaceutical Qbd
Gmp Manufactuirng
Spray Drying
Peptide Drug Delivery
Controlled Release
Oral Solid Dosage Form
Inhalation
Hplc
Ocular Drug Delivery
Nanoparticles
Scalability
Pharmaceutical Industry
Differential Scanning Calorimetry
Quality By Design
Cell Culture
Cmc
Cro
Drug Development
Gmp
Drug Delivery
Pharmaceutics
Technology Transfer
Drug Discovery
Clinical Development
In Vitro
Cro Management
High Performance Liquid Chromatography

Languages:

English
Mandarin

Yun Mo

view source

Yun Na Mo

view source

Us Patents

Milnacipran Formulations
view source
US Patent:

20100286260, Nov 11, 2010
Filed:

May 5, 2010
Appl. No.:

12/774446
Inventors:

Mahendra G. Dedhiya - Pomona NY, US
Anil Chhettry - Holtsville NY, US
Yan Yang - Roslyn Heights NY, US
Yun Mo - Commack NY, US
Bhaveshkumar H. Kothari - Smithtown NY, US
Assignee:

Forest Laboratories Holdings Ltd. - Hamilton
International Classification:

A61K 31/365
A61P 1/08
A61P 25/22
A61P 13/00
A61P 1/12
US Classification:

514470
Abstract:

The present invention provides formulations comprising milnacipran or pharmaceutically acceptable salts thereof (e.g., milnacipran hydrochloride), including immediate release formulations and modified formulations, such as delayed release and extended release formulations. The present invention provides formulations with improved stability and high bioavailability. Processes for preparing the formulations as well as methods of treating conditions by administering the formulations are also described.

Linaclotide Compositions
view source
US Patent:

20140018307, Jan 16, 2014
Filed:

Mar 13, 2013
Appl. No.:

13/799982
Inventors:

Forest Laboratories Holdings Ltd. - , US
Matthew Miller - Kew Gardens NY, US
Andreas Grill - Hauppauge NY, US
Yun Mo - Dix Hills NY, US
Mohammad Mafruhul Bari - Lake Grove NY, US
International Classification:

C07K 7/08
US Classification:

514 211
Abstract:

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

Linaclotide Compositions
view source
US Patent:

20200222541, Jul 16, 2020
Filed:

Jan 11, 2019
Appl. No.:

16/245446
Inventors:

- Hamilton, BM
Matthew Miller - Maplewood NJ, US
Andreas Grill - Hauppauge NY, US
Yun Mo - Dix Hills NY, US
Mohammad Mafruhul Bari - Lake Grove NY, US
Matthew Ronsheim - Port Jefferson NY, US
Joseph Stainkamp - Holtsville NY, US
International Classification:

A61K 47/22
C07K 7/08
A61K 9/16
A61K 38/10
A61K 9/00
A61K 47/02
A61K 47/18
A61K 47/26
A61K 9/50
Abstract:

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

Linaclotide Compositions
view source
US Patent:

20170281774, Oct 5, 2017
Filed:

Mar 17, 2017
Appl. No.:

15/461923
Inventors:

- Hamilton, BM
Matthew Miller - Kew Gardens NY, US
Andreas Grill - Hauppauge NY, US
Yun Mo - Dix Hills NY, US
Mohammad Mafruhul Bari - Lake Grove NY, US
Matthew Ronsheim - Port Jefferson NY, US
Joseph Stainkamp - Holtsville NY, US
International Classification:

A61K 47/22
A61K 47/26
A61K 47/18
A61K 47/02
A61K 9/50
A61K 9/16
A61K 38/10
C07K 7/08
A61K 9/00
Abstract:

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

Linaclotide Compositions
view source
US Patent:

20160324968, Nov 10, 2016
Filed:

Mar 11, 2016
Appl. No.:

15/068454
Inventors:

- Hamilton, BM
Matthew Miller - Kew Gardens NY, US
Andreas Grill - Hauppauge NY, US
Yun Mo - Dix Hills NY, US
Mohammad Mafruhul Bari - Lake Grove NY, US
Matthew Ronsheim - Port Jefferson NY, US
Joseph Stainkamp - Holtsville NY, US
International Classification:

A61K 47/22
A61K 38/10
A61K 47/26
A61K 47/18
A61K 9/50
A61K 9/00
A61K 47/02
Abstract:

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

Linaclotide Compositions
view source
US Patent:

20150005241, Jan 1, 2015
Filed:

Sep 18, 2014
Appl. No.:

14/489718
Inventors:

- Hamilton, BM
Matthew Miller - Kew Gardens NY, US
Andreas Grill - Hauppauge NY, US
Yun Mo - Dix Hills NY, US
Mohammad Mafruhul Bari - Lake Grove NY, US
Matthew Ronsheim - Port Jefferson NY, US
Joseph Stainkamp - Holtsville NY, US
International Classification:

A61K 38/10
A61K 9/00
A61K 47/26
A61K 47/18
A61K 47/02
A61K 47/22
US Classification:

514 211
Abstract:

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.